Clinical trials: Antipsychotic Agents
Bipolar Disorder (BD)
Body Weight Changes After Switching to Lurasidone for Antipsychotic-induced Weight Gain in Bipolar Disorder
Study Objective: To evaluate the treatment effectiveness and safety by analyzing prescription patterns in a routine clinical practice setting and observing changes in clinical indicators (weight, BMI, HAM-D, CGI-S, CGI-I) among…
- Trial name
- NCT07834112
- Testing
- Lurasidone
- Where
- South Korea
- Volunteers
- 155 people
- Sponsor
- Dong-Wook Kim
Schizophrenia
Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center inpatient study to evaluate the efficacy and safety of LB-102 in adult patients diagnosed with acutely exacerbated schizophrenia.
- Trial name
- NCT06179108
- Testing
- LB-102
- Where
- 25 sites in United States
- Volunteers
- 359 people
- Sponsor
- LB Pharmaceuticals Inc.
Overweight, Hyperlipidemia
The Effect of Switching to Aripiprazole on Heart Health in Overweight and Obese Patients With Schizophrenia
This is a 2-year study proposing to examine the effects of aripiprazole on heart health factors such as serum lipids, serum leptin, fasting blood sugar, body weight and blood pressure.
- Conditions
- Overweight, Hyperlipidemia, Cardiovascular Diseases
- Trial name
- NCT00222833
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Pittsburgh
Schizophrenia
Oxcarbazepine as an Adjunct of Antipsychotic Therapy in Acute Schizophrenia
Over recent years an approach with the adjunctive administration of various anticonvulsant drugs has been discussed and a limited number of open and controlled studies were performed for carbamazepine, valproic acid, and…
- Trial name
- OXC-SCZ (NCT00637234)
- Testing
- Oxcarbazepine
- Where
- 2 sites in Germany
- Volunteers
- 54 people
- Sponsor
- University of Cologne
Schizophrenia
FYS Study: Epidemiological, Multicentre, Cross-sectional Study in a Clinical Practice Environment, About the Relationship Between Functioning Status and the Quality of Sleep Perceived by Schizophrenic Outpatients in Spain
The purpose of this study is to establish the relationship between performance of patients with schizophrenia and relationship with perceived quality of sleep.
- Trial name
- NCT01376492
- Testing
- Functioning assessment, Quality of sleep assessment
- Volunteers
- 709 people
- Sponsor
- Janssen-Cilag, S.A.
Psychotic Disorders
Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics
This study will test the effectiveness of two different treatments for children and adolescents who have gained weight on their antipsychotic medications.
- Trial name
- IMPACT (NCT00806234)
- Testing
- Aripiprazole or Perphenazine, Metformin, Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine
- Where
- 4 sites in United States
- Volunteers
- 127 people
- Sponsor
- Johns Hopkins University
MDD
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
To investigate the efficacy and safety of flexibly dosed adjunctive brexpiprazole treatment in active adults with MDD, 18 to 35 years old, who are experiencing an inadequate selective serotonin reuptake inhibitor (SSRI)/serotonin…
- Trial name
- NCT02013609
- Testing
- Brexpiprazole
- Where
- 24 sites in United States
- Volunteers
- 48 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
A Study Evaluating the Treatment Selection and Outcome When Changing Antipsychotic Treatment in Schizophrenic Patients
The purpose of the study is to evaluate the outcome of treatment switch defined as an improvement in CGI-CB scale (Clinical Global Impression - Clinical Benefit).
- Trial name
- ETOS (NCT00999895)
- Where
- 43 sites in Greece
- Volunteers
- 574 people
- Sponsor
- AstraZeneca
Psychosis
Niapsan as Add -on Therapy to Antipsychotic Treatment in First Episode Psychosis
The purpose of this study is to help understand if by adding Niaspan FCT (study drug) to antipsychotic medications will it help maintain or improve cognitve functioning.
- Trial name
- NCT01720095
- Testing
- Niaspan
- Where
- Canada
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Nova Scotia Health Authority
Schizophrenia, Schizophreniform Disorder
Omega-3 Dietary Supplements in Schizophrenia
This 16-week placebo-control study looks to investigate whether patients with schizophrenia for two years or less may benefit from omega-3 supplements.
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT01786239
- Testing
- Risperidone, Omega-3 capsules
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Delbert Robinson
Akathisia, Drug-Induced, Antipsychotic Agents
Study of Preladenant for the Treatment of Neuroleptic Induced Akathisia (Study P05145)
This study is designed to evaluate the effectiveness of preladenant in the prevention (Part 1) or treatment (Part 2) of antipsychotic induced akathisia in participants with acute psychosis using the Barnes Akathisia Scale.
- Conditions
- Akathisia, Drug-Induced, Antipsychotic Agents, Movement Disorders
- Trial name
- NCT00693472
- Testing
- Preladenant, Anticholinergic agents or propanolol, Haloperidol
- Volunteers
- 46 people
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia
A Randomized, Double-blind, Comparison of the Efficacy and Safety of Amisulpride Versus Low-dose Amisulpride Plus Low-dose Sulpiride in the Treatment of Schizophrenia
Background: Surveys have shown that antipsychotic drug combinations are frequently prescribed. Amisulpride, an atypical antipsychotic agent, has low incidence of extrapyramidal symptom (EPS) but with high cost compared to…
- Trial name
- NCT01615185
- Testing
- full-dose amisulpride
- Where
- Taiwan
- Volunteers
- 96 people
- Sponsor
- Kaohsiung Kai-Suan Psychiatric Hospital
Schizophrenia
Quality of Life in Schizophrenic Patients
This is a non-interventional study evaluating quality of life in schizophrenic patients treated with atypical antipsychotics, in the ambulatory setting. This is a 9-month, observational, multicentric prospective study.
- Trial name
- Quality (NCT00597168)
- Where
- 45 sites in Belgium
- Volunteers
- 124 people
- Sponsor
- AstraZeneca
Dementia
Improving Well-being and Health for People With Dementia
800,000 people in the United Kingdom (UK)have dementia, of which 250,000 are living in care homes. These individuals have complex mental health problems, disabilities and social needs, which if unmet will continue to adversely…
- Trial name
- WHELD (NCT01855152)
- Testing
- Optimised WHELD intervention, Treatment as usual
- Where
- United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- professor Clive Ballard
Schizophrenia
A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients
The primary objective of this study was to assess time to discontinuation due to lack of tolerability among patients with schizophrenia receiving LY2140023, given orally twice daily for 24 weeks, versus those on atypical…
- Trial name
- NCT00845026
- Testing
- LY2140023, aripiprazole, olanzapine
- Where
- 23 sites in United States, Germany and 2 more
- Volunteers
- 261 people
- Sponsor
- Denovo Biopharma LLC
Schizophrenia Spectrum and Other Psychotic Disorders, Periodontal Diseases
Antipsychotic Induced Hyperprolactinemaia as Risk Factor for Periodontitis in Schizophrenic Patients
The aim of the present cohort retrospective study is to explore the effect of antipsychotics on periodontal health and the possible effect of antipsychotic-induced hyperprolactinemia as a risk factor for periodontal disease…
- Trial name
- NCT06040944
- Testing
- antipsychotic drugs inducing hyperprolactinemia
- Where
- Egypt
- Volunteers
- 64 people
- Sponsor
- Fayoum University
Post-traumatic Stress Disorder (PTSD)
Discontinuing Psychotropic Medication Before Psychotherapy for PTSD
Post-traumatic stress disorder (PTSD) is commonly treated with trauma-focused psychotherapy, including prolonged exposure therapy and eye movement desensitization and reprocessing (EMDR).
- Trial name
- NCT07802158
- Volunteers
- 100 people
- Sponsor
- Academic Centre for Dentistry in Amsterdam
Schizophrenia
Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia
The purpose of this study is to investigate the effects of flexibly dosed Brexpiprazole monotherapy in the improvement of early-episode schizophrenia through the assessment of social functioning, efficacy, and tolerability.
- Trial name
- NCT02013622
- Testing
- Brexpiprazole
- Where
- 22 sites in United States
- Volunteers
- 49 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Mental Illness
Behavioral Intervention to Reduce Novel Antipsychotic Medication Health Risks
This study will evaluate the effectiveness of a cognitive behavioral treatment in reducing significant medical risk factors often associated with people who have a serious mental illness and are taking atypical antipsychotic…
- Trial name
- NCT00709345
- Testing
- Cognitive behavioral sessions, Time-matched attention control sessions
- Volunteers
- 333 people
- Sponsor
- Medical College of Wisconsin
Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders
Sex, Psychopharmacology, and Diabetes
The term sexual (SD) dysfunction covers conditions that prevent people from having a satisfactory sex life. SD is a frequent and sometimes debilitating complication of mental illness and a known adverse reaction to…
- Conditions
- Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders, Diabetes Mellitus, PreDiabetes
- Trial name
- SECRET (NCT05951660)
- Testing
- Educational intervention
- Where
- Denmark
- Volunteers
- 256 people
- Sponsor
- Zealand University Hospital